Skip to main content

John L. Hays, MD

So that our learners can better understand your experience, investigational interests, and expertise in cancer immunotherapy and multi-modal management of ovarian cancer can you kindly share your current role and affiliations?

So that our learners can better understand your experience, investigational interests, and expertise in cancer immunotherapy and multi-modal management of ovarian cancer can you kindly share your current role and affiliations?

John L. Hays, MD

While the formidable challenges of treating platinum-resistant ovarian cancer are well known, can you summarize the current, approaches for treating these patient cohorts, and specifically, the trigger points and reported outcomes for immunotherapy?

While the formidable challenges of treating platinum-resistant ovarian cancer are well known, can you summarize the current, approaches for treating these patient cohorts, and specifically, the trigger points and reported outcomes for immunotherapy?

John L. Hays, MD

$Given the refractoriness of platinum-resistant OC what does the investigational immunotherapy landscape look like for this patient subset with OC, including the use of immune checkpoint inhibitors and cytokine fusion proteins such as nemvaleukin?$ Video

Given the refractoriness of platinum-resistant OC what does the investigational immunotherapy landscape look like for this patient subset with OC, including the use of immune checkpoint inhibitors and cytokine fusion proteins such as nemvaleukin?

John L. Hays, MD

What novel engineering features of the cytokine fusion protein, nemvaleukin, give you reason to believe that deploying this immunotherapy might potentiate the effectiveness of ICIs in the setting of ovarian cancer and other solid tumors?

What novel engineering features of the cytokine fusion protein, nemvaleukin, give you reason to believe that deploying this immunotherapy might potentiate the effectiveness of ICIs in the setting of ovarian cancer and other solid tumors?

John L. Hays, MD

What were the design, rationale, inclusionary criteria, and results of the ARTISTRY-1 trial, in which nemvaleukin was evaluated in a Phase 1 trial to elucidate dosing and signals suggesting efficacy across a broad range of solid tumors?

What were the design, rationale, inclusionary criteria, and results of the ARTISTRY-1 trial, in which nemvaleukin was evaluated in a Phase 1 trial to elucidate dosing and signals suggesting efficacy across a broad range of solid tumors?

John L. Hays, MD

Based on the results/signals observed in OC patients in ARTISTRY-1, how do you design a translationally optimal trial with nemvaleukin to assess its effectives as a monotherapeutic vs. combinatorial agent?

Based on the results/signals observed in OC patients in ARTISTRY-1, how do you design a translationally optimal trial with nemvaleukin to assess its effectives as a monotherapeutic vs. combinatorial agent?

John L. Hays, MD

Based on the strong signals for OC observed with nemvaleukin in ARTISTRY-1 and the yet-to-be-validated role of ICIs in OC, how did you approach and concretize the design of the ARTISTRY-7 trial focused on persons with platinum-resistant OC?

Based on the strong signals for OC observed with nemvaleukin in ARTISTRY-1 and the yet-to-be-validated role of ICIs in OC, how did you approach and concretize the design of the ARTISTRY-7 trial focused on persons with platinum-resistant OC?

John L. Hays, MD

What were the specific endpoints for ARTISTRY-7 and how will the trial results translate into possible approvals for nemvaleukin and/or ICIs for platinum-resistant ovarian cancer (PROC)?

What were the specific endpoints for ARTISTRY-7 and how will the trial results translate into possible approvals for nemvaleukin and/or ICIs for platinum-resistant ovarian cancer (PROC)?

John L. Hays, MD

Based on the accumulated data thus far from ARTISTRY-1 and interim monitoring, can you characterize the side effect profile and regimen discontinuation rates observed thus far for nemvaleukin, and its manageability in the outpatient setting?

John L. Hays, MD

In addition to the ARTISTRY-7 nemvaleukin trial, what other I-O strategies are being investigated in PROC?

In addition to the ARTISTRY-7 nemvaleukin trial, what other I-O strategies are being investigated in PROC?

John L. Hays, MD

Looking forward, when can we expect early data reporting from ARTISTRY-7 and what are we likely to learn about single agent vs. combinatorial approaches based on nemvaleukin? And why was nemvaleukin fast-tracked by the FDA?

Looking forward, when can we expect early data reporting from ARTISTRY-7 and what are we likely to learn about single agent vs. combinatorial approaches based on nemvaleukin? And why was nemvaleukin fast-tracked by the FDA?

John L. Hays, MD

How was IL-2 re-engineered to generate a cytokine fusion protein that selectively binds to the intermediate-affinity IL-2 receptor and activates antitumor cytolytic effector natural killer cells and CD8+ T cells while minimizing expansion of Tregs?

How was IL-2 re-engineered to generate a cytokine fusion protein that selectively binds to the intermediate-affinity IL-2 receptor and activates antitumor cytolytic effector natural killer cells and CD8+ T cells while minimizing expansion of Tregs?

John L. Hays, MD

What do you hope to learn from ARTISTRY-7 as it relates to the efficacy and safety of nemvaleukin as monotherapy or as part of combinatorial therapy with immune checkpoint inhibitors and, even, chemotoxic agents in the setting of solid tumors?

What do you hope to learn from ARTISTRY-7 as it relates to the efficacy and safety of nemvaleukin as monotherapy or as part of combinatorial therapy with immune checkpoint inhibitors and, even, chemotoxic agents in the setting of solid tumors?

John L. Hays, MD